Summary
Quest Diagnostics Incorporated (DGX) reported its second-quarter 2010 financial results, showing a slight decrease in net revenues compared to the prior year, primarily driven by a decline in clinical testing volume. Despite the revenue dip, the company demonstrated effective cost management, leading to an increase in operating income for the quarter. Earnings per share saw an improvement, partly due to a lower share count from ongoing share repurchase programs. Management highlighted the potential positive long-term impact of U.S. healthcare reform on industry-wide utilization, though it also acknowledged anticipated fee schedule reductions. The company remains focused on operational efficiency, cost control, and managing its financial resources effectively, including continued share buybacks and dividend payments. While facing some legal and regulatory scrutiny, the company believes its current reserves and insurance coverage are adequate and does not anticipate a material adverse effect on its financial condition.
Financial Highlights
56 data points| Revenue | $1.87B |
| Cost of Revenue | $1.08B |
| Gross Profit | $795.76M |
| SG&A Expenses | $419.41M |
| Operating Expenses | $1.51B |
| Operating Income | $365.89M |
| Interest Expense | -$36.64M |
| Net Income | $194.62M |
| EPS (Basic) | $1.08 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 178.92M |
| Shares Outstanding (Diluted) | 180.76M |
Key Highlights
- 1Net revenues for the three months ended June 30, 2010, were $1.87 billion, a decrease of 1.4% from the prior year, with clinical testing volume down 1.3%.
- 2Income from continuing operations for the three months ended June 30, 2010, increased to $194.6 million ($1.07 per diluted share) from $188.2 million ($1.00 per diluted share) in the prior year period.
- 3Operating income for the quarter was $365.9 million, an increase from $359.4 million in the prior year, reflecting effective cost management and a higher operating margin (19.5% vs. 18.9%).
- 4The company repurchased 3.3 million shares of common stock for $175 million in the second quarter of 2010, contributing to a lower share count and improved EPS.
- 5Cash provided by operating activities for the first six months of 2010 was $448.4 million, a significant increase from $263.6 million in the prior year period.
- 6Quest Diagnostics highlighted that U.S. healthcare reform legislation is expected to be a net positive for the industry long-term due to expanded coverage, though it anticipates specific fee schedule reductions.
- 7The company maintained its quarterly cash dividend of $0.10 per common share and has $324 million remaining under its share repurchase authorization.